Your best source on science and technology news from Washington state

Provided by AGP

Sci-Tech Seattle: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Seattle.

Press releases published on May 8, 2026

3 E Network Launches Proactive Financing Strategy to Accelerate Semiconductor Blueprint, Officially Establishing Chip Business Unit
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
Avicanna Announces Results of Annual General and Special Meeting
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)
illumin Reports First Quarter 2026 Financial Results
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
Hyperion DeFi Announces Closing of Public Offering of Common Stock
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
GigaCloud Technology Inc to Participate in 21st Annual Needham Technology, Media, & Consumer Conference
Sagtec Global Limited Strengthens Smart Property Development Collaboration Following Stateight Sdn Bhd’s Industry Recognition
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
Castellum Announces First Quarter 2026 Financial Results
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Share us

on your social networks:

Sign up for:

Sci-Tech Seattle

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.